Intersect ENT (NASDAQ:XENT) and Encision (OTCMKTS:ECIA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.
Valuation & Earnings
This table compares Intersect ENT and Encision’s top-line revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Encision has lower revenue, but higher earnings than Intersect ENT.
This table compares Intersect ENT and Encision’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Risk & Volatility
Intersect ENT has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Encision has a beta of -0.22, indicating that its stock price is 122% less volatile than the S&P 500.
This is a breakdown of current ratings and price targets for Intersect ENT and Encision, as reported by MarketBeat.com.
||Strong Buy Ratings
Intersect ENT currently has a consensus target price of $18.14, indicating a potential upside of 41.19%. Given Intersect ENT’s higher possible upside, analysts clearly believe Intersect ENT is more favorable than Encision.
Insider and Institutional Ownership
87.7% of Intersect ENT shares are held by institutional investors. 3.5% of Intersect ENT shares are held by insiders. Comparatively, 35.7% of Encision shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Intersect ENT beats Encision on 6 of the 11 factors compared between the two stocks.
Intersect ENT Company Profile
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Encision Company Profile
Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. It provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. The company's AEM instruments product line includes a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. It also provides various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; AEM EndoShield 2 burn protection systems; and AEM Burn Protection Cable, as well as markets AEM monitor product line that is used in conjunction with AEM instruments. The company sells its products through a network of direct and independent sales representatives. Encision Inc. was founded in 1991 and is based in Boulder, Colorado.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.